Due to Patient Survival Top line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer Namoden

to Patient Survival Top line Results of the Namodenoson Phase II

Liver Cancer Trial Expected Q1/19

TIKVA, Israel, October 31, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing

a pipeline of proprietary small molecule drugs that address cancer, liver, and inflammatory diseases, today provided an update

on its Phase II clinical trial of drug candidate Namodenoson (CF102) for the treatment of advanced hepatocellular carcinoma (HCC)

in patients with Child Pugh B whose disease has progressed on sorafenib therapy. Due to patient survival, top line efficacy results

are expected during the first quarter of 2019.

of 78 patients was completed in August 2017 and the trial continues treating subjects in a blinded fashion (either Namodenoson

25 mg BID or matching placebo).

statistical plan for this trial requires that the primary efficacy analysis occurs when no more than 3 of the original 78 patients

survive. At the outset of the trial, it was assumed that patients with advanced HCC with Child-Pugh B had a relatively poor prognosis,

and that within approximately a year of enrollment of the last subject, primary efficacy analysis could be conducted. In order

to maintain the statistical integrity of the trial as well as adhere to the principles of Good Clinical Practice, the Company

estimates that it will un-blind the data during Q1/19.

CEO, Dr. Pnina Fishman, commented, "This unexpectedly prolonged longevity is unquestionably beneficial for the individual

patients, and gives us hope that Namodenoson may eventually prove its value in this patient population."

received Orphan Drug Designation for Namodenoson in Europe and the U.S., as well as Fast Track Status in the U.S. as a second

line treatment for HCC.

is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson

is being evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment

for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells

whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

Can-Fite BioPharma Ltd.

BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology

that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.

The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's

liver cancer drug, Namodenoson, is in Phase II trials for hepatocellular carcinoma (HCC), the most common form of liver cancer,

and for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S.

and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson

has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's

third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating

additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with

experience in over 1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com.

press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among

other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,

strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking

statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"

"expect," "intend," "plan," "may," "should" or "anticipate"

or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate

strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various

filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the

approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected

events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that

have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual

results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could

cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking

statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking

statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and

our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working

capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate

development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical

studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory

filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability

to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model

and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for

intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual

property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political

and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's filings with the

SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are

highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation

to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.